名稱 | BCR(E13)-ABL1(E2)_P210 Fusion |
型號 | CBP20207R |
報價 | |
特點 | BCR(E13)-ABL1(E2)_P210 Fusion |
產品搜索
相關文章
聯(lián)系我們
聯(lián)系人:蔣經理
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
產品展示 / PRODUCTS
- 詳細內容
CBP20207R | |
Format | RNA |
Description | Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes. |
Technical Data | |
Left Gene | BCR |
Right Gene | ABL1 |
Left Breakpoint | chr22:23631808:+(hg19) |
Right Breakpoint | chr9:133729451:+(hg19) |
Buffer | Tris-EDTA |
Product Information | |
Intended Use | Research Use Only |
Unit Size | 1ug |
Concentration | Download for COA |
Purity | Download for COA |
RNA electrophoresis | Download for COA |
Sanger sequencing | |
Storage | -80℃ |
Expiry | 12 months from the date of manufacture |